Drugs that contain Pexidartinib Hydrochloride
1. Turalio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8722702 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(3 years from now) | |
| US9169250 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(3 years from now) | |
| US8404700 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
Nov, 2027
(3 years from now) | |
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(9 years from now) | |
| US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(12 years from now) | |
| US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461169 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity |
Apr, 2028
(4 years from now) | |
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(9 years from now) | |
| US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(12 years from now) | |
| US10435404 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(14 years from now) | |
| US10941142 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(14 years from now) | |
| US10961240 | DAIICHI SANKYO INC | Formulations of a compound modulating kinases |
Jul, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
More Information on Dosage
TURALIO family patents
